Trials / Completed
CompletedNCT04047017
Camrelizumab Combined With Apatinib for Recurrent Resistant GTN
Camrelizumab Combined With Apatinib for Recurrent Resistant Gestational Trophoblastic Neoplasia: a Phase 2, Single-arm, Prospective Study
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Peking Union Medical College Hospital · Academic / Other
- Sex
- Female
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This study is to evaluate the efficacy and safety of camrelizumab plus apatinib in patients with high-risk chemo-refractory or relapsed GTN.
Detailed description
Apatinib is an oral small-molecule tyrosine kinase inhibitor that selectively binds to and inhibits VEGF receptor 2. Novel immunotherapy using the immune checkpoint inhibitors such as anti-PD-1 antibody has received much attention. Camrelizumab as one of the anti-PD-1 drug have impressive clinical activity.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Apatinib | 250mg, po, qd |
| DRUG | Camrelizumab | 200mg, q2w |
Timeline
- Start date
- 2019-08-08
- Primary completion
- 2021-03-18
- Completion
- 2021-05-15
- First posted
- 2019-08-06
- Last updated
- 2021-07-30
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04047017. Inclusion in this directory is not an endorsement.